Newman Dignan & Sheerar Inc’s Oncolytics Biotech ONCY Stock Holding History

Newman Dignan & Sheerar Inc’s Portfolio ONCY Stock Details ONCY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-22,915	Closed	-$17.7K	–	190
2025 Q2	$17.7K	Hold	22,915	–	–	﹤0.01%	192
2025 Q1	$12.6K	Hold	22,915	–	–	﹤0.01%	174
2024 Q4	$20.9K	Buy	22,915 +900	+4%	+$937	0.01%	178
2024 Q3	$26.9K	Buy	+22,015	New	+$21.6K	0.01%	184
2024 Q1	–	Sell	-22,015	Closed	-$29.7K	–	179
2023 Q4	$29.7K	Buy	+22,015	New	+$34.4K	0.01%	175
2023 Q3	–	Sell	-18,915	Closed	-$49.2K	–	176
2023 Q2	$49.2K	Hold	18,915	–	–	0.02%	181
2023 Q1	$22.7K	Hold	18,915	–	–	0.01%	190
2022 Q4	$30.8K	Buy	18,915 +6,000	+46%	+$9.11K	0.01%	185
2022 Q3	$16	Buy	+12,915	New	+$15.8K	﹤0.01%	180
2022 Q2	–	Sell	-12,915	Closed	-$20	–	195
2022 Q1	$20	Sell	12,915 -1,000	-7%	-$1.68K	﹤0.01%	194
2021 Q4	$19K	Buy	13,915 +1,000	+8%	+$1.85K	0.01%	201
2021 Q3	$27K	Buy	+12,915	New	+$29.2K	0.01%	191

Other funds holding ONCY

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Seeds Investor New York $735M AUM 17.54% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

IAIM

International Assets Investment Management Orlando, Florida $1.67B AUM 28.26% 1-Year Est. Return

Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

CIBC World Market Toronto, Ontario, Canada $61.3B AUM 39.33% 1-Year Est. Return

Newman Dignan & Sheerar Inc's ONCY Position: Q3 2025 in Review

Newman Dignan & Sheerar Inc sold out of Oncolytics Biotech (ONCY) in Q3 2025, closing a stake of 22,915 shares — an estimated $17.7K sold.

Newman Dignan & Sheerar Inc first reported a position in ONCY in Q3 2021 and held it in 12 quarters. The position peaked at $49.2K in Q2 2023. 56 funds tracked by Wall St. Rank hold ONCY as of Q3 2025.

Newman Dignan & Sheerar Inc reported no remaining Oncolytics Biotech position as of Q3 2025 after selling out during the quarter.
Newman Dignan & Sheerar Inc sold 22,915 Oncolytics Biotech shares in Q3 2025, an estimated $17.7K.
Newman Dignan & Sheerar Inc first reported a position in Oncolytics Biotech in Q3 2021 and held it in 12 quarters.
Newman Dignan & Sheerar Inc's Oncolytics Biotech position peaked at $49.2K in Q2 2023.
56 funds tracked by Wall St. Rank held Oncolytics Biotech as of Q3 2025.

Based on Newman Dignan & Sheerar Inc's 13F filing for Q3 2025, filed 9 Oct 2025.